BPC-157 vs IGF-1 LR3 vs Ipamorelin
A three-way comparison to help you find the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | IGF-1 LR3 | Ipamorelin |
|---|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. |
| Best For |
What They Have in Common
BPC-157, IGF-1 LR3, Ipamorelin are all commonly used for:
Key Differences
Unique to IGF-1 LR3:
Unique to Ipamorelin:
Detailed Analysis
Commonalities
Both BPC-157 and IGF-1 LR3 are commonly used for Muscle Growth, Recovery & Healing.
Which Should You Choose?
BPC-157 has stronger evidence for Recovery & Healing. IGF-1 LR3 has stronger evidence for Muscle Growth.
Commonalities
Both BPC-157 and Ipamorelin are commonly used for Muscle Growth, Recovery & Healing.
Which Should You Choose?
BPC-157 has stronger evidence for Recovery & Healing. Ipamorelin has stronger evidence for Muscle Growth.
Commonalities
Both IGF-1 LR3 and Ipamorelin are commonly used for Muscle Growth, Fat Loss, Recovery & Healing.
Which Should You Choose?
Ipamorelin has stronger evidence for Fat Loss.